- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00429299
Neoadjuvant Study With Chemotherapy, Lapatinib And Trastuzumab In Breast Cancer (CHERLOB)
22. februar 2016 oppdatert av: GlaxoSmithKline
Chemotherapy Plus Lapatinib or Trastuzumab or Both in Her2+ Primary Breast Cancer. A Randomized Phase IIb Study With Biomarker Evaluation.
Evaluate the activity of Trastuzumab, Lapatinib, and a combination of both agents with chemotherapy in the preoperative (neoadjuvant) treatment of early breast cancer.
Studieoversikt
Status
Fullført
Forhold
Studietype
Intervensjonell
Registrering (Faktiske)
121
Fase
- Fase 2
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
-
Cremona, Italia, 26100
- GSK Investigational Site
-
Pavia, Italia, 27100
- GSK Investigational Site
-
Perugia, Italia, 06156
- GSK Investigational Site
-
Reggio Emilia, Italia, 42100
- GSK Investigational Site
-
Varese, Italia, 21100
- GSK Investigational Site
-
-
Emilia-Romagna
-
Carpi (MO), Emilia-Romagna, Italia, 41012
- GSK Investigational Site
-
Forlì, Emilia-Romagna, Italia, 47100
- GSK Investigational Site
-
Modena, Emilia-Romagna, Italia, 41100
- GSK Investigational Site
-
Parma, Emilia-Romagna, Italia, 43100
- GSK Investigational Site
-
Piacenza, Emilia-Romagna, Italia, 29100
- GSK Investigational Site
-
Rimini, Emilia-Romagna, Italia, 47900
- GSK Investigational Site
-
-
Lombardia
-
Treviglio (BG), Lombardia, Italia, 24047
- GSK Investigational Site
-
-
Piemonte
-
Candiolo (TO), Piemonte, Italia, 10060
- GSK Investigational Site
-
-
Puglia
-
Brindisi, Puglia, Italia, 72100
- GSK Investigational Site
-
-
Toscana
-
Pisa, Toscana, Italia, 56126
- GSK Investigational Site
-
-
-
-
-
Warszawa, Polen, 00-909
- GSK Investigational Site
-
-
-
-
-
Berlin, Tyskland, 13125
- GSK Investigational Site
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år til 65 år (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Hunn
Beskrivelse
Inclusion criteria:
- Histologically confirmed infiltrating primary breast cancer of > 2.0 cm in largest clinical diameter
HER2 positive tumor (either IHC 3+ or FISH+)
- Availability of tumor tissue suitable for biological and molecular examination before starting primary treatment
- Age >18, < 65 years
- ECOG PS 0-1
- Normal organ and marrow function as defined below:
leukocytes ³ 3000/microL
absolute neutrophil count ³ 1,500/microL
platelets ³ 100,000/microL
total bilirubin <= 1.5x ULN. In case of Gilbert's syndrome, <2 x ULN is allowed
AST (SGOT)/ALT(SGPT)<= 2.5 X institutional upper limit of normal
Alkaline phosphatase <= 2.5 x ULN
Creatinine within normal institutional limits
- Cardiac ejection fraction within the institutional range of normal as measured by echocardiogram or MUGA scan
- Eligibility of patients receiving medications or substances known to affect, or with the potential to affect the activity or pharmacokinetics of lapatinib will be determined following review of their use by the Principal Investigator. A list of medications and substances known or with the potential to interact with CYP450 isoenzymes is provided
- The effects of lapatinib on the developing human fetus at the recommended therapeutic dose are unknown; women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately, the patient should be apprised of the potential hazard to the fetus and potential risk for loss of the pregnancy
- Ability to understand and the willingness to sign a written informed consent document
- Ability to swallow and retain oral medication
Exclusion criteria:
- Stage IIIB, IIIC, and inflammatory breast cancer
- Stage IV breast cancer
- Contraindication to the treatment with anthracycline, paclitaxel and/or trastuzumab
- Prior treatment with chemotherapy, endocrine therapy or radiotherapy. Prior treatment with EGFR targeting therapies
- Treatment with any other investigational agents, or with all herbal (alternative) medicines
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to lapatinib
- Uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Pregnancy or breastfeeding; (breast feeding should be discontinued to be enrolled in the study)
- Women of childbearing potential that refusal to adopt adequate contraceptive measures
- HIV-positive patients receiving combination anti-retroviral therapy
- GI tract disease resulting in an inability to take oral medication, malabsorption syndrome, a requirement for IV alimentation, prior surgical procedures affecting absorption, uncontrolled inflammatory GI disease (e.g., Crohn's, ulcerative colitis)
- Concomitant requirement for medication classified as CYP3A4 inducers or inhibitors
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Aktiv komparator: Arm A
Chemotherapy plus trastuzumab
|
First dose 4mg/kg in 60mins, then weekly 2mg/kg in 30 mins
Andre navn:
80mg/sqm 1 hour infusion for 12 weeks
Andre navn:
600mg/sqm iv day 1 q21 days for four coursess
75mg/sqm iv day 1 q21 days for four courses
600mg/sqm day 1 q21 days for four courses
|
Eksperimentell: Arm B
Chemotherapy plus lapatinib
|
80mg/sqm 1 hour infusion for 12 weeks
Andre navn:
600mg/sqm iv day 1 q21 days for four coursess
75mg/sqm iv day 1 q21 days for four courses
600mg/sqm day 1 q21 days for four courses
Arm B 1250mg/d PO Arm C 750mg/d PO
Andre navn:
|
Aktiv komparator: Arm C
Chemotherapy plus trastuzumab plus lapatinib
|
First dose 4mg/kg in 60mins, then weekly 2mg/kg in 30 mins
Andre navn:
80mg/sqm 1 hour infusion for 12 weeks
Andre navn:
600mg/sqm iv day 1 q21 days for four coursess
75mg/sqm iv day 1 q21 days for four courses
600mg/sqm day 1 q21 days for four courses
Arm B 1250mg/d PO Arm C 750mg/d PO
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Percentage of Participants With Pathological Complete Response (pCR) in the Breast and in the Lymph Nodes
Tidsramme: At Baseline and surgery (within 5 weeks after the last chemotherapy administration) (assessed up to Study Week 29)
|
Pathological Complete Response (pCR) is defined by the complete absence of infiltrating tumor cells in the breast and in the lymph nodes.
The pathological response in the breast was evaluated according to the criteria of Miller and Payne as follows: Grade 1, no change or some alteration to individual malignant cells, but no reduction in overall cellularity; Grade 2, a minor loss in tumor cells (up to 30%); Grade 3, between an estimated 30% and 90% reduction in tumor cells; Grade 4, marked disappearance of tumor cells, with only a small cluster or a dispersed cell remaining (more than 90% loss); Grade 5, no identifiable malignant cells.
Ductal carcinoma in situ (DCIS) may be present.
Grades were interpreted as follows: Grade 1-2=no response; Grade 3-4=partial response; Grade 5=complete response.
pCR was defined by comparing specimens obtained at Baseline (biopsy) to those obtained upon surgery.
|
At Baseline and surgery (within 5 weeks after the last chemotherapy administration) (assessed up to Study Week 29)
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Percentage of Participants With the Indicated Clinical Objective Response (Complete Response and Partial Response), Stable Disease, and Progressive Disease, as Assessed by Ultrasonography
Tidsramme: At Baseline and after primary treatment (within 2 weeks before surgery; up to Study Week 27)
|
The clinical response was evaluated by comparing the tumor size (largest tumor diameter) before (at Baseline [biopsy]) and after treatment (before surgery), as assessed by ultrasonography examination.
The clinical response was scored by Response Evaluation Criteria in Solid Tumors (RECIST) as follows: complete clinical response: the nodule is not detectable and all the ultrasound abnormality detected at diagnosis disappeared (margins circumscribed, round oval shape, parallel orientation, isoechoic echo pattern, no posterior acoustic features, echogenic lesion boundary, and tumor vascularity not present); partial clinical response: the longest diameter of the tumor has been reduced by >50%, and the ultrasound characteristics of the tumor persist; no response (stable disease): the longest diameter of the tumor has been reduced by <50% or has increased by no more than 20% from the starting value; progressive disease: tumor longest diameter has increased >20% from the starting value.
|
At Baseline and after primary treatment (within 2 weeks before surgery; up to Study Week 27)
|
Percentage of Participants Who Had Breast-conserving Surgery (BCS), Mastectomy, and Conversion From Mastectomy to BCS
Tidsramme: At Baseline and at surgery (up to Study Week 29)
|
The percentage of participants who had BCS and mastectomy and who were initiallycandidates for mastectomy and who actually had BCS was measured.
At Baseline, the surgeon stated, within 4 weeks before starting the primary treatment, which type of surgical treatment he would perform in the absence of primary therapy and in the case of primary therapy (if the tumor size was reduced by the primary treatment to less than 3 centimeters), and the reasons for these choices.
The rules for choosing the type of surgical treatment are reported in the Consensus Conference on Primary Treatment of Early Breast Cancer.
The surgeon was to have re-evaluated the participant after primary treatment.
In cases in which the type of surgical procedure was different from that originally programmed, the reason for this chance was to have been reported.
|
At Baseline and at surgery (up to Study Week 29)
|
Time to Treatment Failure From the Start of Primary Therapy
Tidsramme: From randomization up to Study Week 307
|
Time to treatment failure (TTF) is defined as the interval of time between the date of randomization and the earliest date of disease progression, premature treatment discontinuation and death due to any cause.
The overall disease progression date is the earlier of the two disease progression dates from ultrasonography and mammography assessments.
For ultrasonography, disease progression is defined as at least 20% increase in the longest diameter of the primary lesion at pre-surgery comparing to Baseline.
For mammography, disease progression is defined as at least 20% increase in the larger nodule dimension at pre-surgery comparing to Baseline.
For participants who has neither progressed, pre-maturely withdrawn or died, time to treatment failure will be censored at the latest date of ultrasonography and mammography tumor assessments.
|
From randomization up to Study Week 307
|
Number of Participants With Treatment Failure
Tidsramme: From randomization up to 29 weeks
|
Treatment failure is defined as the occurrence of local tumor progression (including ipsilateral and controlateral breast), distant tumor progression, permanent treatment discontinuation (either for the experimental or conventional arm), or death due to any cause.
|
From randomization up to 29 weeks
|
Percentage of Inhibition of Biomarkers Ki67, pAKT, pMAPK, Tunel Test, PTEN, and pEGFR After Treatment
Tidsramme: At Baseline and Withdrawal (assessed up to Study Week 29)
|
The percentage of inhibition of intermediate (EGFR, HER2, pMAPK, pAKT, PTEN, and PI3KCA) and final (TUNEL and Ki67) biomarkers of the proliferation and apoptosis pathways was calculated as the difference between the staining scores before (Baseline [biopsy]) and after treatment (withdrawal).
|
At Baseline and Withdrawal (assessed up to Study Week 29)
|
Number of Participants With Any Adverse Event (AE), Including Serious Adverse Events (SAEs), Occurring in >=5% of Participants
Tidsramme: From the first dose of randomized therapy to 30 days after the last dose of randomized therapy (assessed up to Study Week 29)
|
An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect.
Medical or scientific judgment had been exercised in deciding whether reporting was appropriate in other situations.
|
From the first dose of randomized therapy to 30 days after the last dose of randomized therapy (assessed up to Study Week 29)
|
Number of Variations/Somatic Mutation in PI3KCA at Baseline
Tidsramme: Baseline
|
Analysis of mutations in the PI3KCA gene was performed from RNA extracted from frozen tumor tissue samples (sections).
A gene is either a wild-type (no mutation) or mutated (presence of a mutation).
Exons 9 and 20 of the PI3KCA gene were accessed (high frequency mutation at these two spots).
|
Baseline
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Publikasjoner og nyttige lenker
Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.
Generelle publikasjoner
- Guarneri V, Frassoldati A, Bottini A, Cagossi K, Bisagni G, Sarti S, Ravaioli A, Cavanna L, Giardina G, Musolino A, Untch M, Orlando L, Artioli F, Boni C, Generali DG, Serra P, Bagnalasta M, Marini L, Piacentini F, D'Amico R, Conte P. Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study. J Clin Oncol. 2012 Jun 1;30(16):1989-95. doi: 10.1200/JCO.2011.39.0823. Epub 2012 Apr 9.
- Guarneri V, Dieci MV, Griguolo G, Miglietta F, Girardi F, Bisagni G, Generali DG, Cagossi K, Sarti S, Frassoldati A, Gianni L, Cavanna L, Pinotti G, Musolino A, Piacentini F, Cinieri S, Prat A, Conte P; of the CHER-Lob study team. Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial. Eur J Cancer. 2021 Aug;153:133-141. doi: 10.1016/j.ejca.2021.05.018. Epub 2021 Jun 19.
- Guarneri V, Dieci MV, Frassoldati A, Maiorana A, Ficarra G, Bettelli S, Tagliafico E, Bicciato S, Generali DG, Cagossi K, Bisagni G, Sarti S, Musolino A, Ellis C, Crescenzo R, Conte P. Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer. Oncologist. 2015 Sep;20(9):1001-10. doi: 10.1634/theoncologist.2015-0138. Epub 2015 Aug 5.
- Guarneri V, Generali DG, Frassoldati A, Artioli F, Boni C, Cavanna L, Tagliafico E, Maiorana A, Bottini A, Cagossi K, Bisagni G, Piacentini F, Ficarra G, Bettelli S, Roncaglia E, Nuzzo S, Swaby R, Ellis C, Holford C, Conte P. Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer. J Clin Oncol. 2014 Apr 1;32(10):1050-7. doi: 10.1200/JCO.2013.51.4737. Epub 2014 Mar 3.
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart
1. august 2006
Primær fullføring (Faktiske)
1. juni 2012
Studiet fullført (Faktiske)
1. juni 2012
Datoer for studieregistrering
Først innsendt
29. januar 2007
Først innsendt som oppfylte QC-kriteriene
29. januar 2007
Først lagt ut (Anslag)
31. januar 2007
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
22. mars 2016
Siste oppdatering sendt inn som oppfylte QC-kriteriene
22. februar 2016
Sist bekreftet
1. januar 2016
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Hudsykdommer
- Neoplasmer
- Neoplasmer etter nettsted
- Bryst sykdommer
- Brystneoplasmer
- Fysiologiske effekter av legemidler
- Molekylære mekanismer for farmakologisk virkning
- Enzymhemmere
- Antirevmatiske midler
- Antimetabolitter, antineoplastisk
- Antimetabolitter
- Antineoplastiske midler
- Immunsuppressive midler
- Immunologiske faktorer
- Tubulin modulatorer
- Antimitotiske midler
- Mitosemodulatorer
- Antineoplastiske midler, Alkylering
- Alkyleringsmidler
- Myeloablative agonister
- Antineoplastiske midler, fytogene
- Topoisomerase II-hemmere
- Topoisomerasehemmere
- Antineoplastiske midler, immunologiske
- Proteinkinasehemmere
- Antibiotika, antineoplastisk
- Cyklofosfamid
- Paklitaksel
- Trastuzumab
- Fluorouracil
- Epirubicin
- Lapatinib
Andre studie-ID-numre
- EGF106988
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Neoplasmer, bryst
-
Guangzhou First People's HospitalFullført
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital og andre samarbeidspartnereFullførtThe Clinical Application Guide of Conebeam Breast CTKina
-
Novartis PharmaceuticalsFullførtMetastatisk brystkreft (MBC) | Locally Advance Breast Cancer (LABC)Storbritannia, Spania
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.UkjentHR-positiv, HER2-negativ og PIK3CA Mutation Advanced Breast CancerKina
-
Rabin Medical CenterFullførtDesmoid fibromatose | Desmoid | Desmoid fibromatose i huden | Desmoid Neoplasm of Chest Wall | Desmoid-svulst forårsaket av somatisk mutasjon | Aggressive fibromatoser | Fibromatose DesmoidIsrael
-
Emory UniversityNational Cancer Institute (NCI)TilbaketrukketPrognostisk stadium IV brystkreft AJCC v8 | Metastatisk malign neoplasma i hjernen | Metastatisk brystkarsinom | Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8
-
NRG OncologyNational Cancer Institute (NCI)Aktiv, ikke rekrutterendeAnatomisk stadium IV brystkreft AJCC v8 | Prognostisk stadium IV brystkreft AJCC v8 | Metastatisk malign neoplasma i beinet | Metastatisk malign neoplasma i lymfeknutene | Metastatisk malign neoplasma i leveren | Metastatisk brystkarsinom | Metastatisk malign neoplasma i lungen | Metastatisk malign neoplasma... og andre forholdForente stater, Canada, Saudi-Arabia, Korea, Republikken
Kliniske studier på trastuzumab
-
National Cancer Institute (NCI)NRG OncologyAktiv, ikke rekrutterendeDuktalt brystkarsinom in situForente stater, Canada, Puerto Rico, Korea, Republikken
-
Tanvex BioPharma USA, Inc.FullførtBrystkreft | Brystneoplasmer | HER2-positiv brystkreft | Stadium II brystkreft | Stadium IIIA Brystkreft | Brystkreft i tidlig stadiumHviterussland, Chile, Georgia, Ungarn, India, Mexico, Peru, Filippinene, Den russiske føderasjonen, Ukraina
-
Spanish Breast Cancer Research GroupFullført
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRekrutteringHER2-positiv brystkreft | Brystkreft i tidlig stadium | Adjuvant behandling etter Trastuzumab | RCB-klassifisering 1-2 | NeratiniKina
-
Fudan UniversityHoffmann-La RocheUkjent
-
NRG OncologyNational Cancer Institute (NCI)RekrutteringTilbakevendende spyttkjertelkarsinom | Stage III Major spyttkjertelkreft AJCC v8 | Stage IV Major spyttkjertelkreft AJCC v8 | Metastatisk spyttkjertelkarsinom | Ikke-opererbart spyttkjertelkarsinomForente stater
-
Fudan UniversityFullført
-
Samsung Bioepis Co., Ltd.AvsluttetBrystneoplasmerUkraina, Romania, Den russiske føderasjonen, Frankrike, Bulgaria, Tsjekkia, Polen
-
University Medical Center GroningenFullført
-
National Cancer Institute (NCI)Aktiv, ikke rekrutterendeMannlig brystkarsinom | Stage IIA brystkreft AJCC v6 og v7 | Stage IIB brystkreft AJCC v6 og v7 | Stage IIIA brystkreft AJCC v7 | Stage IIIB brystkreft AJCC v7 | Stage IIIC brystkreft AJCC v7Forente stater, Puerto Rico